Early Detection Research Network

Biomarker Detection Using NAPPA Tumor Antigen Arrays: EDRN Supplement

The overall goal of this project application for the EDRN set-aside funds is to focus our collaborative efforts to identify p53 mutation-specific antibody biomarkers in breast, prostate, and ovarian cancer. P53-specific gene mutations are frequent in multiple cancer types. Of the common solid tumors, p53 mutations have been identified in 50% of lung and ovarian cancers, 45% of colon cancers, 20% of breast cancers, and 10-30% of prostate cancers (The p53 Mutation Handbook, T. Soussi, http://p53/free/fr). The most common mutations vary from cancer to cancer, with 50 point mutations covering the 10 most common mutations for all major solid tumors
190-biomarker-detection-using-nappa-tumor-antigen
7fa2b5ef67854d9ea161c6658537c5a5
7fa2b5ef67854d9ea161c6658537c5a5
Contents

There are currently no items in this folder.